Tech Company Financing Transactions
Prevail Therapeutics Funding Round
On 3/9/2018, Prevail Therapeutics landed $75 million in Series A investment from Adage Capital Management, Alexandria Venture Investments and Boxer Capital.
Transaction Overview
Company Name
Announced On
3/9/2018
Transaction Type
Venture Equity
Amount
$75,000,000
Round
Series A
Investors
Proceeds Purpose
The proceeds of the Series A financing will be used to advance Prevail's pipeline of AAV-based (adeno-associated virus) therapeutics targeting lysosomal dysfunction to treat patients with genetically-defined neurodegenerative diseases.
Company Information
Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
430 East 29th St. 1520
New York, NY 10016
USA
New York, NY 10016
USA
Phone
Website
Email Address
Overview
Prevail Therapeutics is a biotech company based in New York City that is developing therapeutics for brain disorders such as Parkinson's disease. Prevail is establishing a pipeline of programs that includes discovery-phase and preclinical development efforts.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Asa Abeliovich
Chief Financial Officer
Brett Kaplan
Chief Medical Officer
Jeffrey Sevigny
Chief Technical Officer
Yong Dai
VP - Bus. Development
Franz Hefti
VP - Bus. Development
Emily Minkow
VP - General Counsel
Kira Schwartz
Browse more venture capital transactions:
Prev: 3/9/2018: Mojio venture capital transaction
Next: 3/9/2018: Zebi venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on all VC transactions involving tech companies. VC investment data records reported here are sourced from a variety of public sources. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs